Form 483

Aurobindo Pharma Limited Form 483, 2012-09-21

FDA issued a Form 483 to Aurobindo Pharma Limited on 2012-09-21 with 7 public-safe observations.

483· Form 483 issued7 observations

Aurobindo Pharma Limited · Sangareddy, India · Issued September 21, 2012

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 Sep 2012
21 CFR 211.22(a)

Approve or reject components, products

Cited by Eileen A Liu, Torrance J Slayton, Stephen J Koniers

21 Sep 2012
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Eileen A Liu, Torrance J Slayton, Stephen J Koniers

21 Sep 2012
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Eileen A Liu, Torrance J Slayton, Stephen J Koniers

21 Sep 2012
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Eileen A Liu, Torrance J Slayton, Stephen J Koniers

21 Sep 2012
21 CFR 211.165(a)

Testing and release for distribution

Cited by Eileen A Liu, Torrance J Slayton, Stephen J Koniers

Inspected site

APAurobindo Pharma LimitedSangareddy, India

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(b)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 7 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere